RESUMO
Objective To explore the clinical effect of Tongluo-Ningxue decoction for hematuria from IgA nephropathy. Methods A total of 60 patients with IgA nephropathy in the hospital between July 2015 and August 2016 were randomly divided into two groups, with 30 cases in each group. The control group was treated with western medicine (Benazepril Hydrochloride plus dipyridamole), whereas the observation group took Tongluo-Ningxue decoction for treatment. The clinical efficacy, clinical symptom score, biochemical index and humoral immune index in the two groups were compared. Results The effective rate was 86.7％ (26/30) in the observation group, and 63.3％ (19/30) in the control group, with the difference between the two groups being statistically significant (χ2=4.356, P=0.037). After treatment, the scores of fatigue and weakness (0.7 ± 0.1 vs. 1.4 ± 0.2, t=18.954), soreness and weakness of waist and knees (0.7 ± 0.1 vs. 1.4 ± 0.2, t=21.071), swollen sore throat (0.6 ± 0.1 vs. 1.4 ± 0.2, t=20.723), and hot flashes and night-time sweating (0.6 ± 01 vs. 1.5 ± 0.2, t=20.732) in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the 24h UP (0.53 ± 0.12 g vs. 0.74 ± 0.15 g, t=5.988), RBC (16.84 ± 5.38 vs. 21.42 ± 9.73, t=2.256), SCr (56.34 ± 7.21 μmol/L vs. 61.27 ± 8.45 μmol/L, t=2.431), and IgA (2.35 ± 0.43 g/L vs. 2.62 ± 0.45 g/L, t=2.376) in the observation group were significantly lower than those in the control group (P<0.05). Conclusions The Tongluo-Ningxue decoction can improve the biochemical indicators, enhance immunity, improve renalfunction and relieve clinical symptoms, and therefore, it is worthwhile for the clinical application.